Status | Study |
NOT_YET_RECRUITING |
Study Name: Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab Condition: Hemophilia A Date: 2023-10-23 Interventions: Emicizumab in Hemophilia A |
RECRUITING |
Study Name: Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects Condition: Hemophilia A Date: 2023-07-31 Interventions: In each dose level, 6 subjects will be assigned to TU7710.Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, |
NOT_YET_RECRUITING |
Study Name: Liver Biopsy Following Gene Therapy For Hemophilia Condition: Hemophilia A Date: 2023-06-27 Interventions: Standard transjugular liver biopsy under moderate sedation |
RECRUITING |
Study Name: A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A Condition: Hemophilia A Date: 2023-05-12 Interventions: Given per investigator's discretion |
RECRUITING |
Study Name: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Condition: Hemophilia A Date: 2023-03-16 Interventions: Administered as SC injection. |
Active, not recruiting |
Study Name: Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA�) in France Condition: Hemophilia A Date: 2022-07-04 Interventions: Other: HEMOPHAR e-learning programtraining on professional practice by following HEMOPHAR e-learning program |
NOT_YET_RECRUITING |
Study Name: Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A Condition: Hemophilia A Date: 2022-02-10 Interventions: Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antib |
RECRUITING |
Study Name: Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis Condition: Hemophilia A Date: 2021-08-23 Interventions: Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A |
RECRUITING |
Study Name: SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Condition: Hemophilia A Date: 2020-09-21 Interventions: Personalized dose of aPCC-emicizumab will be administered to participants.The max dose allowed for aPCC will be 25 U/kg/dose every 8 h |
RECRUITING |
Study Name: UPLC-MS/MS Monitoring of Emicizumab Therapy Condition: Hemophilia A Date: 2020-07-10 |